Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

By M. Brines, P. Ghezzi, Sonja Keenan, D. Agnello, N. Lanerolle, C. Cerami, L. Itri, A. Cerami. Proceedings of the National Academy of Sciences of the United States of America, 2000

1,458 citations recorded by the source corpus.

Subfields: Genetics, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/6eb3c2e59828bfc836aaa3795798a1162dadfd74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. B. Kwon
2. H. Ehrenreich
3. W. Tetzlaff
4. J. Grauer
5. J. Beiner
6. C. Dembowski
7. A. Vaccaro
8. L. Cepek

Citations in the corpus

• Pathophysiology and pharmacologic treatment of acute spinal cord injury. (2004, background): “Erythropoeitan is thought to have anti-inflammatory, antioxidant and antiapoptotic properties [138–141] and in addition to demonstrating neuroprotection in the setting of experimental brain injury [142] has been shown to prevent motor neuron apoptosis and improve neurologic function in a global isch”
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial (2002, methodology): “Although a variety of in vivo and in vitro studies show that EPO is also protective of excessive (neurotoxic) excitation (4,14), the protection observed here appears to mainly target later events (e.g., apoptosis or inflammation subsequent to brain injury) ( 4 ).”